The treatment of women with epilepsy;Behandlung von frauen mit epilepsie

Deutsches Arzteblatt

Volumn 107, Issue 45, 2010, Pages 787-793

  Weil, Sabine ^a   Deppe, Charlotte ^b   Noachtar, Soheyl ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Klinik und Poliklinik fur Frauenheilkunde und Geburtshilfe   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CHLORMADINONE ACETATE; CLOMIFENE; CYPROTERONE ACETATE; DESOGESTREL; DIENOGEST; DROSPIRENONE; ETHINYLESTRADIOL; ETHOSUXIMIDE; ETIRACETAM; FOLIC ACID; GABAPENTIN; GESTODENE; GONADORELIN; HARKOSERIDE; LAMOTRIGINE; LEVONORGESTREL; LYNESTRENOL; NORETHISTERONE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; SEX HORMONE BINDING GLOBULIN; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; ZONISAMIDE;

ANTICONVULSANT THERAPY; BONE METABOLISM; BREAST FEEDING; CHILDBIRTH; CLEFT LIP; CLEFT PALATE; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CONTRACEPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; EPILEPSY; HUMAN; HYPERINSULINEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; INTRAUTERINE CONTRACEPTIVE DEVICE; NEURAL TUBE DEFECT; OVARY POLYCYSTIC DISEASE; PREGNANCY; PROGENY; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; WEIGHT GAIN;

ABNORMALITIES, DRUG-INDUCED; ABORTION, SPONTANEOUS; ANTICONVULSANTS; CONTRACEPTIVES, ORAL; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INDUCTION; EPILEPSY; FEMALE; FOLIC ACID; GERMANY; HUMANS; INFANT, NEWBORN; POLYCYSTIC OVARY SYNDROME; PRECONCEPTION CARE; PREGNANCY; RISK FACTORS;

EID: 79851483346     PISSN: 00121207     EISSN: 01722107     Source Type: Journal    
DOI: 10.3238/arztebl.2010.0787     Document Type: Review

References (25)

1. Yerby MS: Quality of life, epilepsy advances, and the evolving role of anticonvulsants in women with epilepsy. Neurology 2000; 55: 21-31; discussion 54-28.
2. May TW, Pfafflin M, Coban I, Schmitz B: Frauen und Epilepsie: Befürchtungen, Wissen, Beratungsbedarf. Nervenarzt 2009; 80: 174-83.
3. Herzog AG: Catamenial epilepsy: definition, prevalence, pathophysiology, and treatment. Seizure 2008; 17: 151-9.
4. Herzog AG, Klein P, Ransil BJ: Three patterns of catamenial epilepsy. Epilepsia 1997; 38: 1082-8. (Pubitemid 27424151)
5. Foldvary-Schaefer N, Falcone T: Catamenial epilepsy: pathophysiology, diagnosis, and management. Neurology 2003; 61: 2-15.
6. Bauer J: Interactions between hormones and epilepsy in female patients. Epilepsia 2001; 42(Suppl 3): 20-2.
7. Bilo L, Meo R: Epilepsy and polycystic ovary syndrome: where is the link? Neurol Sci 2006; 27: 221-30.
8. Herzog AG, Schachter SC: Valproate and the polycystic ovarian syndrome: final thoughts. Epilepsia 2001; 42: 311-5. (Pubitemid 32275907)
9. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV: Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993; 329: 1383-8. (Pubitemid 23317348)
10. Rauchenzauner M, Haberlandt E, Scholl-Burgi S, et al.: Effect of valproic acid treatment on body composition, leptin and the soluble leptin receptor in epileptic children. Epilepsy Res 2008; 80: 142-9.
11. Pylvanen V, Pakarinen A, Knip M, Isojarvi J: Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav 2006; 8: 643-8.
12. Schwenkhagen AM, Stodieck SR: Which contraception for women with epilepsy? Seizure 2008; 17: 145-50.
13. O'Brien MD, Guillebaud J: Contraception for women with epilepsy. Epilepsia 2006; 47: 1419-22. (Pubitemid 44393853)
14. Christensen J, Petrenaite V, Atterman J, et al.: Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia 2007; 48: 484-9. (Pubitemid 46365201)
15. Winawer MR, Shinnar S: Genetic epidemiology of epilepsy or what do we tell families? Epilepsia 2005; 46(Suppl 10): 24-30.
16. Eurap Study Group: Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology 2006; 66: 354-60.
17. Pennell PB: 2005 AES annual course: evidence used to treat women with epilepsy. Epilepsia 2006; 47(Suppl 1): 46-53.
18. Morrow J, Russell A, Guthrie E, et al.: Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77: 193-8.
19. Harden CL, Meador KJ, Pennell PB, et al.: Practice parameter update: management issues for women with epilepsy - focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009; 73: 133-41.
20. Schmitz B, Denning, D, Dietz, R, Steinhoff B, Mayer, T: Valproate for women with epilepsy; a recommendation of the German Chapter of international League against Epilepsy. Eurap homepage: wwweurap.de 2010.
21. Marson AG, Al-Kharusi AM, Alwaidh M, et al.: The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369: 1016-26. (Pubitemid 46436125)
22. Meador KJ, Baker GA, Browning N, et al.: Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009; 360: 1597-605.
23. Harden CL, Pennell PB, Koppel BS, et al.: Practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009; 73: 142-9.
24. Bagshaw J, Crawford P, Chappell B: Problems that mothers' with epilepsy experience when caring for their children. Seizure 2008; 17: 42-8. (Pubitemid 350257000)
25. Bartl R: Antiepileptika-induzierte Osteopathie. Formen, Pathogenese, Prophylaxe, Früherkennung, Therapie. Dtsch Med Wochenschr 2007; 132: 1475-9.